Home / Stocks / Gujarat Themis Biosyn Ltd
GUJTHEM

Gujarat Themis Biosyn Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹359.2

Change

-3.6 (-0.99%)

Open

₹362.8

Prev. Close

₹362.8

Day High

₹362.8

Day Low

₹355.1

Volume Analysis

Traded

43,519

Delivered

25,412

Delivery %

58.39%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (46.0%)

Weaknesses (2)

  • •High debt-to-equity ratio (1.42)
  • •Promoter holding is falling

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹370.66 ₹366.73 ₹362.96 ₹359.03 ₹355.26 ₹351.33 ₹347.56
Fibonacci ₹366.73 ₹363.79 ₹361.97 ₹359.03 ₹356.09 ₹354.27 ₹351.33
Camarilla ₹361.32 ₹360.61 ₹359.91 ₹359.03 ₹358.49 ₹357.79 ₹357.08

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-18.47%

1 Week

-7.32%

1 Month

+2.35%

3 Months

-5.77%

6 Months

-2.58%

1 Year

-15.05%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹89.01

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

17.13%

Net margin 28.31% × asset turnover 0.5x × equity multiplier 1.21x

Company Overview

Sector

Healthcare

Market Cap

₹4,659 Cr

P/E (TTM)

239.0

ROE

16.2%

Book Value

₹78.6

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Gujarat Themis Biosyn Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 50/100. The strongest factor is Business Quality (91/100), while Risk & Volatility (19/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (46.0%); high debt-to-equity ratio (1.42); promoter holding is falling. FII holding has been rising.

TopFund Score — Fundamentals Quality

50/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

34

Growth

32

Valuation

22

Cash Flow

75

Corporate Governance

43

Momentum

54

Institutional Ownership

62

Business Quality

91

Risk & Volatility

19

Liquidity

48

From Screener.in

  • −Stock is trading at 4.58 times its book value
  • −Promoter holding has decreased over last quarter: -11.5%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Recording of Analysts Meet held on 16.11.2026

Please refer to the attached Analysts Presentation

Newspaper Publication of Un-Audited Financial Results (Standalone & Consolidated) for the Quarter and Half Year ended 30.09.2026

Company Secretary and Compliance Officer Vineet Gawankar resigned effective 30 November 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 Sep 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 40 39 42 39 35 40 38 36 42 44 44 50
Expenses + 23 21 21 20 19 21 22 22 21 25 23 51
Operating Profit 17 18 21 19 15 19 16 14 21 19 21 -1
OPM % 42.0% 46.0% 50.0% 48.0% 44.0% 48.0% 42.0% 39.0% 49.0% 44.0% 48.0% -1.8%
Other Income + 1 1 1 1 0 0 1 0 1 1 0 3
Interest 0 0 0 0 0 0 0 0 0 2 2 8
Depreciation 1 1 1 1 1 2 1 2 3 4 4 5
Profit before tax 17 18 21 18 14 17 16 12 19 14 15 -11
Tax % 26.0% 26.0% 24.0% 26.0% 26.0% 25.0% 25.0% 25.0% 24.0% 24.0% 27.0% 24.0%
Net Profit + 13 13 16 13 11 13 12 9 14 11 11 -14
EPS in Rs 1 1 1 1 1 1 1 1 1 1 1 -1
Raw PDF — — — — — — — — — — — —
YoY Sales growth -17 38 52 -22 -12 2 -10 — — — 22 18

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026
Sales + 31 33 36 39 41 85 91 115 148 170 151 166
Expenses + 25 27 30 33 34 53 50 57 75 91 82 90
Operating Profit 7 6 6 6 7 32 40 58 74 79 69 76
OPM % 21.0% 19.0% 17.0% 16.0% 18.0% 37.0% 45.0% 51.0% 50.0% 46.0% 46.0% 46.0%
Other Income + 0 0 0 0 2 2 3 4 7 4 2 2
Interest 0 0 0 0 0 1 1 1 0 0 0 3
Depreciation 1 1 1 1 1 1 2 2 3 4 5 13
Profit before tax 5 5 5 5 8 31 41 59 77 79 66 62
Tax % 0.0% 0.0% 10.0% 20.0% 22.0% 24.0% 26.0% 26.0% 25.0% 25.0% 26.0% 25.0%
Net Profit + 5 5 4 4 6 24 30 44 58 59 49 47
EPS in Rs 0 0 0 0 1 2 3 4 5 5 4 4
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 10.0% 0.0% 37.0% 14.0% 12.0% 15.0% 0.0%
Sales growth 4 4 9 9 6 107 6 27 29 14 -11 —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 Sep 2026
Reserves -8 -3 1 5 11 35 63 96 142 194 237 277 1,010
Borrowings + 6 3 4 1 6 8 5 1 0 3 30 162 1,453
Other Liabilities + 9 8 9 8 8 14 14 18 17 17 22 54 197
Total Liabilities 15 15 21 20 33 64 88 122 166 221 301 503 2,674
Fixed Assets + 10 9 11 11 15 17 19 19 33 38 41 289 1,931
CWIP 0 0 0 0 1 0 2 13 21 91 184 121 180
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 5 5 11 10 17 47 67 90 113 92 76 93 562
Total Assets 15 15 21 20 33 64 88 122 166 221 301 503 2,674
Equity Capital 7 7 7 7 7 7 7 7 7 7 11 11 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026
Cash from Operating Activity + 3 4 3 6 1 1 11 40 39 64 91 —
Cash from Investing Activity + 0 -1 -3 -1 -6 -3 -2 -30 -20 -55 -112 —
Cash from Financing Activity + -3 -3 0 -4 5 2 -5 -14 -13 -9 26 —
Net Cash Flow -1 0 0 1 0 0 3 -4 6 0 5 —
Free Cash Flow 2 3 0 5 -5 -3 7 26 16 -10 -25 —
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 44 73 57 99 25 24 51 94 81 107 156 —

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 70.87% → 59.33%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 28.23% 27.26% 26.52% 26.47% 26.55% 26.05% 25.44% 25.01% 26.0% 26.15% 26.18% 24.21%
Promoters 70.87% 70.87% 70.87% 70.87% 70.87% 70.87% 70.87% 70.87% 70.87% 70.86% 70.87% 59.33%
FII 0.86% 1.05% 1.44% 1.49% 1.42% 1.91% 2.51% 2.95% 1.96% 1.8% 1.76% 3.8%
DII 0.04% 0.82% 1.18% 1.17% 1.17% 1.17% 1.17% 1.17% 1.17% 1.17% 1.17% 12.65%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Gujarat Themis Biosyn Ltd (this stock) 4,659 239.0 4.55 16.2%
Aarti Drugs Ltd. 4,589 19.9 2.73 13.4%
Sms Pharmaceuticals Ltd. 4,758 40.7 5.64 14.3%
Zota Health Care Limited 4,492 — 7.17 -15.0%
Gufic Biosciences Ltd. 4,415 55.1 6.21 10.1%
Kwality Pharmaceuticals L 4,370 45.3 11.31 22.6%
Morepen Lab. Ltd 5,061 26.8 3.67 5.33%

Which Mutual Funds Hold Gujarat Themis Biosyn Ltd?

Frequently Asked Questions about Gujarat Themis Biosyn Ltd

Community Sentiment

What are other investors saying about Gujarat Themis Biosyn Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.